The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
in vitro
and
in vivo
models of multiple myeloma by blockade of Ikaros and MYC signaling
The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
in vitro
and
in vivo
models of multiple myeloma by blockade of Ikaros and MYC signaling
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started